The Na+-Ca2+ exchange inhibitor KB-R7943 and related compounds exhibit pharmacological properties that may be helpful in designing selective treatments for cardiac, neuronal, and kidney diseases.
This review highlights the pharmacological properties of NCX inhibitors like KB-R7943, which may aid in designing more selective treatments for cardiac and other diseases.
The Na+-Ca2+ exchange (NCX) system plays a pivotal role in regulating intracellular Ca2+ concentration in cardiomyocytes, neuronal cells, kidney and a variety of other cells. It performs a particularly important function in regulating cardiac contractility and electrical activity. One of the leading NCX inhibitors is KB-R9743 (KBR) that appears to exhibit selectivity for Ca2+-influx-mode NCX activity (reverse mode of NCX). In this article we reviewed pharmacology of KBR and provide a brief summary of studies with other NCX inhibitors, such as SEA0400 (SEA) and SN-6 (SN). Potential clinical usefulness of KBR and other NCX inhibitors is still controversial but the reviewed findings may be helpful in designing more selective and clinically useful NCX inhibitors for the treatment of cardiac, neuronal and kidney diseases.
Amran et al. (Mon,) conducted a review in Cardiac, neuronal, and kidney diseases. KB-R7943 (KBR) and other NCX inhibitors was evaluated. The Na+-Ca2+ exchange inhibitor KB-R7943 and related compounds exhibit pharmacological properties that may be helpful in designing selective treatments for cardiac, neuronal, and kidney diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: